Advertisement

Drugs Acting on the Lower Urinary Tract

  • D. Tincello

Abstract

In this chapter the drugs available for the treatment of lower urinary tract (LUT) disorders are described, with the exception of antibiotics for urinary tract infections. The discussion is limited to prescribed medications, which are grouped according to diagnoses.

Keywords

Stress Incontinence Detrusor Overactivity Interstitial Cystitis Detrusor Instability Genuine Stress Incontinence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Diokno AC, Lapides J (1972) Oxybutynin: a new drug with analgesic and anticholinergic properties. J Urol 108: 307–9.PubMedGoogle Scholar
  2. 2.
    Massad CA, Kogan BA, Trigo-Rocha FE (1992) The pharma- 18. cokinetics of intravesical and oral oxybutynin chloride. J Urol 148: 595–7.PubMedGoogle Scholar
  3. 3.
    Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and 19. its therapeutic use in detrusor instability. Drugs Aging 6: 243–62.PubMedCrossRefGoogle Scholar
  4. 4.
    Kirkali Z, Whitaker RH (1987) The use of oxybutynin in 20. urological practice. Int Urol Nephrol 19: 385–91.PubMedCrossRefGoogle Scholar
  5. 5.
    Tapp AJ, Cardozo LD, Versi E, Cooper D (1990) The treatment of detrusor instability in post-menopausal women 21. with oxybutynin chloride: a double blind placebo controlled study [see comments]. Brit J Obstet Gynaecol 97: 521–6.CrossRefGoogle Scholar
  6. 6.
    Riva D, Casolati E (1984) Oxybutynin chloride in the treat- 22. ment of female idiopathic bladder instability. Results from double blind treatment. Clin Exp Obstet Gynecol 11: 37–42.PubMedGoogle Scholar
  7. 7.
    Moisey CU, Stephenson TP, Brendler CB (1980) The urodynamic and subjective results of treatment of detrusor insta- 23. bility with oxybutynin chloride. Br J Urol 52: 472–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A medium-term analysis of the subjective efficacy of treat- 24. ment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 104: 988–93.PubMedCrossRefGoogle Scholar
  9. 9.
    Tincello DG, Adams EJ, Sutherst JR, Richmond DH (2000) 25. Oxybutynin for detrusor instability with adjuvant salivary stimulant pastilles to improve compliance: results of 26. a multicentre, randomised controlled trial. BJU Int 85: 416–20.Google Scholar
  10. 10.
    Brendler CB, Radebaugh LC, Mohler JL (1989) Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 141: 1350–2. 27.Google Scholar
  11. 11.
    Enzelsberger H, Helmer H, Kurz C (1995) Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Br J Obstet Gynaecol 102: 28. 929–30.PubMedGoogle Scholar
  12. 12.
    Greenfield SP, Fera M (1991) The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol 146: 532–4. 29.Google Scholar
  13. 13.
    Jonas U, Hofner K, Madersbacher H, Holmdahl TH (1997) Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symp- 30. toms of frequency, urge incontinence, and urgency: urodynamic evaluation. Int Study Group World J Urol 15: 144–51. 31.Google Scholar
  14. 14.
    Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B (1997) Tolterodine - a new bladder-selective antimuscarinic agent. Eur J Pharm 327: 195–207. 32.Google Scholar
  15. 15.
    Abrams P, Freeman RM, Anderström C, Mattiason A (1996) Efficacy and tolerability of tolterodine vs oxybutynin and placebo in patients with detrusor instability. J Urol 157 (Suppl): 103.Google Scholar
  16. 16.
    Drutz HP, Appell RA (1997) Enhanced tolerability of toltero- 33 dine compared to oxybutynin in an controlled clinical study. Int Urogynecol J 8 (Suppl): S14.Google Scholar
  17. 17.
    Appell RA (1997) Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 50: 90–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Abrams P, Freeman R, Anderström C, Mattiasson A (1998) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81: 801–10.PubMedCrossRefGoogle Scholar
  19. 19.
    Kobelt G, Kirchberger I, Malone-Lee J (1999) Quality of life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int 83: 583–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Guarneri L, Robinson E, Testa R (1994) A review of flavoxate: pharmacology and mechanism of action. Drugs Today 30: 91–8.Google Scholar
  21. 21.
    Delaere KP, Michiels HG, Debruyne FM, Moonen WA (1977) Flavoxate hydrochloride in the treatment of detrusor instability. Urol Int 32: 377–81.PubMedCrossRefGoogle Scholar
  22. 22.
    Thuroff JW, Bunke B, Ebner A et al. (1991) Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 145: 813–16.PubMedGoogle Scholar
  23. 23.
    Castleden CM, Duffin HM, Gulati RS (1986) Double-blind study of imipramine and placebo for incontinence due to bladder instability. Age Ageing 15: 299–303.PubMedCrossRefGoogle Scholar
  24. 24.
    Lose G, Jorgensen L, Thunedborg P (1989) Doxepin in the treatment of female detrusor overactivity: a randomized double-blind crossover study. J Urol 142: 1024–6.PubMedGoogle Scholar
  25. 25.
    Sultana CJ, Walters MD (1995) Estrogen and urinary incontinence in women. Maturitas 20: 129–38.CrossRefGoogle Scholar
  26. 26.
    Fantl JA, Cardozo LD, McClish DK (1994) Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis: first report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 83: 12–18.PubMedGoogle Scholar
  27. 27.
    Cardozo LD, Kelleher CJ (1995) Sex hormones, the menopause and urinary problems. Gynaecol Endocrinol 9: 75–84.CrossRefGoogle Scholar
  28. 28.
    Ek A, Andersson KE, Gullberg B, Ulmsten U (1978) The effects of long-term treatment with norephedrine on stress incontinence and urethral closure pressure profile. Scand J Urol Nephrol 12: 105–10.PubMedCrossRefGoogle Scholar
  29. 29.
    Lehtonen T, Rannikko S, Lindell O et al. (1986) The effect of phenylpropanolamine on female stress urinary incontinence. Ann Chir Gynaecol 75: 236–41.PubMedGoogle Scholar
  30. 30.
    Lose G, Rix P, Diernaes E, Alexander N (1988) Norfenefrine in the treatment of female stress incontinence. A double-blind controlled trial. Urol Int 43: 11–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Kinn A, Lindskog M (1988) Estrogens and phenylpropanolamine in combination for stress urinary incontinence in postmenopausal women. Urology 32: 273–80.PubMedCrossRefGoogle Scholar
  32. 32.
    Ahlstrom K, Sandahl B, Sjoberg B et al. (1990) Effect of combined treatment with phenylpropanolamine and estriol, compared with estriol treatment alone in postmenopausal women with stress urinary incontinence. Gynecol Obstet Invest 30: 37–43.PubMedCrossRefGoogle Scholar
  33. 33.
    Erickson DR, Davies MF (1998) Interstitial cystitis. Int Urogynecol J 9: 174–83CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2002

Authors and Affiliations

  • D. Tincello

There are no affiliations available

Personalised recommendations